Medicus Sciences Acquisition (Medicus Sciences Acquisition) Research & Development : $0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Medicus Sciences Acquisition Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Medicus Sciences Acquisition's Research & Development for the three months ended in Sep. 2022 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

Medicus Sciences Acquisition Research & Development Historical Data

The historical data trend for Medicus Sciences Acquisition's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Sciences Acquisition Research & Development Chart

Medicus Sciences Acquisition Annual Data

Trend

Dec20

Dec21

Research & Development

Medicus Sciences Acquisition Quarterly Data
	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Research & Development	Get a 7-Day Free Trial			-	-	-	-	-

Medicus Sciences Acquisition Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Medicus Sciences Acquisition (NAS:MSAC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medicus Sciences Acquisition Research & Development Related Terms

Thank you for viewing the detailed overview of Medicus Sciences Acquisition's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicus Sciences Acquisition (Medicus Sciences Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Medicus Sciences Acquisition Corp (NAS:MSAC) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

152 West 57th Street, Floor 20, New York, NY, USA, 10019

Website

https://www.medicusspac.com

Medicus Sciences Acquisition Corp is a blank check company.

Executives

Eric Cheng	officer: Chief Business Officer	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Kenneth Berkovitz	director	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Christopher Kaster	director	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Ross Levine	director	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Judah Drillick	officer: Chief Financial Officer	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Jacob Gottlieb	director, 10 percent owner, officer: Executive Chairman	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Medicus Sciences Holdings Llc	10 percent owner	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Michael Castor	director, 10 percent owner, officer: Chief Executive Officer	152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019

Medicus Sciences Acquisition (Medicus Sciences Acquisition) Headlines

From GuruFocus

Medicus Sciences Acquisition Corp. Announces Pricing of $80,000,000 Initial Public Offering

By PRNewswire PRNewswire • 02-16-2021

Medicus Sciences Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 02-13-2023

Medicus Sciences Acquisition Corp. Announces Closing of $92,000,000 Initial Public Offering and Full Exercise of the Overallotment Option

By PRNewswire PRNewswire • 02-18-2021